LeukoVantage‑R Myelodysplastic Syndrome (MDS)
Also known as: Myeloid NGS Panel MDS
Use
LeukoVantage‑R MDS is part of the LeukoVantage myeloid neoplasm mutation panels, used for diagnosis, prognosis, and monitoring of myelodysplastic syndromes by detecting mutations in genes relevant to MDS when cytogenetics may be uninformative or equivocal. The panel interrogates multiple genes known to be associated with MDS, aiding in early-stage detection, disease subclassification, and informing treatment strategy.
Special Instructions
Specimen types include whole blood, bone marrow, and extracted DNA, with defined stability conditions depending on storage temperature. Enhanced reporting is available via the Quanum® portal which provides clinical annotation and tabular summaries.
Limitations
The assay has a limit of detection down to approximately 5% allele frequency and may miss mutations below that threshold. A negative result does not entirely exclude MDS, particularly in early stages or cases with non-mutated clonal disease. Cytogenetic abnormalities not interrogated by this panel may require complementary testing.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided
Storage Instructions
Whole blood: acceptable for up to 2 weeks at room temperature (18‑25 °C) or refrigerated (2‑8 °C), not acceptable if frozen
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 2 weeks |
| Refrigerated | 2 weeks |
| Frozen | 3 years |